Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma.
Spear S, Le Saux O, Mirza HB, Iyer N, Tyson K, Grundland Freile F, Walton JB, Woodman C, Jarvis S, Ennis DP, Aguirre Hernandez C, Xu Y, Spiliopoulou P, Brenton JD, Costa-Pereira AP, Cook DP, Vanderhyden BC, Keun HC, Triantafyllou E, Arnold JN, McNeish IA. Spear S, et al. Among authors: le saux o. Cancer Res. 2024 Nov 15;84(22):3772-3787. doi: 10.1158/0008-5472.CAN-23-3890. Cancer Res. 2024. PMID: 39186679 Free PMC article.
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.
Le Saux O, Ardin M, Berthet J, Barrin S, Bourhis M, Cinier J, Lounici Y, Treilleux I, Just PA, Bataillon G, Savoye AM, Mouret-Reynier MA, Coquan E, Derbel O, Jeay L, Bouizaguen S, Labidi-Galy I, Tabone-Eglinger S, Ferrari A, Thomas E, Ménétrier-Caux C, Tartour E, Galy-Fauroux I, Stern MH, Terme M, Caux C, Dubois B, Ray-Coquard I. Le Saux O, et al. Nat Commun. 2024 Jul 16;15(1):5932. doi: 10.1038/s41467-024-47000-5. Nat Commun. 2024. PMID: 39013886 Free PMC article. Clinical Trial.
Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.
Frenel JS, Mathiot L, Cropet C, Borcoman E, Hervieu A, Coquan E, De La Motte Rouge T, Saada-Bouzid E, Sabatier R, Lavaud P, Jimenez M, Legrand F, Le Saux O, Charafe E, Gonçalves A. Frenel JS, et al. Among authors: le saux o. J Immunother Cancer. 2025 Jan 7;13(1):e010708. doi: 10.1136/jitc-2024-010708. J Immunother Cancer. 2025. PMID: 39773562 Free article. Clinical Trial.
[Current advances in immunotherapy in ovarian cancer].
Le Saux O, Dubois B, Stern MH, Terme M, Tartour E, Classe JM, Chopin N, Trédan O, Caux C, Ray-Coquard I. Le Saux O, et al. Bull Cancer. 2020 Apr;107(4):465-473. doi: 10.1016/j.bulcan.2019.11.015. Epub 2020 Feb 20. Bull Cancer. 2020. PMID: 32089245 Review. French.
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial.
Ray-Coquard IL, Savoye AM, Schiffler C, Mouret-Reynier MA, Derbel O, Kalbacher E, LeHeurteur M, Martinez A, Cornila C, Martinez M, Bengrine Lefevre L, Priou F, Cloarec N, Venat L, Selle F, Berton D, Collard O, Coquan E, Le Saux O, Treilleux I, Gouerant S, Angelergues A, Joly F, Tredan O. Ray-Coquard IL, et al. Among authors: le saux o. Nat Commun. 2024 Jul 16;15(1):5931. doi: 10.1038/s41467-024-46999-x. Nat Commun. 2024. PMID: 39013870 Free PMC article. Clinical Trial.
97 results